ERBB2 and neoplasm: Across these studies, the independent prognostic factors associated with poorer survival outcomes included: advanced stage at diagnosis (n = 21) [10, 11, 12, 13, 14, 16, 17, 18, 21, 23, 26, 32, 34, 39, 41, 42, 45, 51, 52, 55, and 61], large tumor size (n = 6) [10, 11, 13, 16, 19, and 42], positive lymph node status (n = 8) [10, 12, 13, 16, 18, 19, 42, and 45], higher histologic grade (n = 3) [12, 13, 39], and HER2‐enriched and triple‐negative molecular subtypes (n = 18) [10, 11, 15, 17, 18, 19, 21, 23, 25, 27, 28, 32, 38, 39, 45, 51, 55, and 61].